<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">06376</article-id><article-id pub-id-type="doi">10.7554/eLife.06376</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology</subject></subj-group></article-categories><title-group><article-title>Mitochondrial Ca<sup>2+</sup> and membrane potential, an alternative pathway for Interleukin 6 to regulate CD4 cell effector function</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-24050"><name><surname>Yang</surname><given-names>Rui</given-names></name><aff><institution content-type="dept">Department of Medicine, Immunobiology Program</institution>, <institution>University of Vermont</institution>, <addr-line><named-content content-type="city">Burlington</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-24051"><name><surname>Lirussi</surname><given-names>Dario</given-names></name><aff><institution content-type="dept">Department of Vaccinology and Applied Microbiology</institution>, <institution>Helmholtz Center for Infection Research</institution>, <addr-line><named-content content-type="city">Braunschweig</named-content></addr-line>, <country>Germany</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-24052"><name><surname>Thornton</surname><given-names>Tina M</given-names></name><aff><institution content-type="dept">Department of Medicine, Immunobiology Program</institution>, <institution>University of Vermont</institution>, <addr-line><named-content content-type="city">Burlington</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-24053"><name><surname>Jelley-Gibbs</surname><given-names>Dawn M</given-names></name><aff><institution>Taconic</institution>, <addr-line><named-content content-type="city">Germantown</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-33016"><name><surname>Diehl</surname><given-names>Sean A</given-names></name><aff><institution content-type="dept">Department of Medicine, Immunobiology Program</institution>, <institution>University of Vermont</institution>, <addr-line><named-content content-type="city">Burlington</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-24055"><name><surname>Case</surname><given-names>Laure K</given-names></name><aff><institution content-type="dept">Department of Medicine, Immunobiology Program</institution>, <institution>University of Vermont</institution>, <addr-line><named-content content-type="city">Burlington</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-33017"><name><surname>Madesh</surname><given-names>Muniswamy</given-names></name><aff><institution content-type="dept">Department of Medical Genetics and Molecular Biochemistry</institution>, <institution>Temple University</institution>, <addr-line><named-content content-type="city">Philadelphia</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-24057"><name><surname>Taatjes</surname><given-names>Douglas J</given-names></name><aff><institution content-type="dept">Department of Pathology and Laboratory Medicine</institution>, <institution>University of Vermont</institution>, <addr-line><named-content content-type="city">Burlington</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-24059"><name><surname>Teuscher</surname><given-names>Cory</given-names></name><aff><institution content-type="dept">Department of Medicine, Immunobiology Program</institution>, <institution>University of Vermont</institution>, <addr-line><named-content content-type="city">Burlington</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-24060"><name><surname>Haynes</surname><given-names>Laura</given-names></name><aff><institution>Trudeau Institute</institution>, <addr-line><named-content content-type="city">Saranac lake</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-23904"><name><surname>Rinc√≥n</surname><given-names>Mercedes</given-names></name><aff><institution content-type="dept">Department of Medicine, Immunobiology Program</institution>, <institution>University of Vermont</institution>, <addr-line><named-content content-type="city">Burlington</named-content></addr-line>, <country>United States</country><email>mrincon@uvm.edu</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1142"><name><surname>Medzhitov</surname><given-names>Ruslan</given-names></name><role>Reviewing editor</role><aff><institution>Howard Hughes Medical Institute, Yale University School of Medicine</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>14</day><month>05</month><year>2015</year></pub-date><volume>4</volume><elocation-id>e06376</elocation-id><supplementary-material><ext-link xlink:href="elife-06376-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>07</day><month>01</month><year>2015</year></date><date date-type="accepted"><day>13</day><month>05</month><year>2015</year></date></history><permissions><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><abstract><p>IL-6 plays an important role in determining the fate of effector CD4 cells and the cytokines that these cells produce. Here we identify a novel molecular mechanism by which IL-6 regulates CD4 cell effector function. We show that IL-6-dependent signal facilitates the formation of mitochondrial respiratory chain supercomplexes to sustain high mitochondrial membrane potential late during activation of CD4 cells. Mitochondrial hyperpolarization caused by IL-6 is uncoupled from the production of ATP by oxidative phosphorylation. However, it is a mechanism to raise the levels of mitochondrial Ca<sup>2+</sup> late during activation of CD4 cells. Increased levels of mitochondrial Ca<sup>2+</sup> in the presence of IL-6 are used to prolong <italic>Il4</italic> and <italic>Il21</italic> expression in effector CD4 cells. Thus, the effect of IL-6 on mitochondrial membrane potential and mitochondrial Ca<sup>2+</sup> is an alternative pathway by which IL-6 regulates effector function of CD4 cells and it could contribute to the pathogenesis of inflammatory diseases.</p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author keywords</title><kwd>effector cytokines</kwd><kwd>IL-6</kwd><kwd>calcium</kwd><kwd>Stat3</kwd><kwd>NFATc2</kwd><kwd>mitochondrion</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All procedures performed on the mice were approved by the Institutional Animal Care and Use Committee (IACUC) of University of Vermont using protocols #12-032 (Rincon), #11-024 (Teuscher) and by the IACUC of Trudeau Institute using protocol #03-005 (Haynes).</p></fn></fn-group></back></article>